Open AccessFive‐year analysis from phase 2 trial of “sandwich” chemoradiotherapy in newly diagnosed, stage IE to IIE , nasal type, extranodal natural killer/T‐cell lymphoma
Author(s) -
Zhang Li,
Jiang Ming,
Xie Li,
Zhang Hong,
Jiang Yu,
Yang Qunpei,
Liu Weiping,
Zhang Wenyan,
Zhuo Hongyu,
Li Ping,
Chen Nianyong,
Zhao Sha,
Wang Feng,
Zou Liqun
Publication year - 2016
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.569
Subject(s) - medicine , vincristine , lymphoma , prednisone , stage (stratigraphy) , odds ratio , chemoradiotherapy , radiation therapy , chop , gastroenterology , t cell lymphoma , survival rate , chemotherapy , oncology , surgery , cyclophosphamide , paleontology , biology
The “sandwich” protocol, was first proposed by us and comprised of l ‐asparaginase, vincristine, and prednisone chemotherapy with radiotherapy, results in 2‐year overall survival and progression‐free survival rates that surpass traditional therapies for patients with newly diagnosed, stage IE ‐ IIE , nasal type, extranodal natural killer/T‐cell lymphoma. The results had been published by cancer. These patients were followed up over a median period of 67 months, for which updates and the results of prognostic factors analyses are presented. The 5‐year overall survival and progress‐free survival rates were both 64%. The highest rates of death occurred during the first 6 months, and between the second and third year after enrollment. The initial therapeutic response (odds ratio = 5.83; P = 0.001) and B symptoms (odds ratio = 6.13; P = 0.043) were significant prognostic factors for overall survival. However, the international prognostic index was not significant for progress‐free survival and overall survival. There were no severe long‐term side effects. These results indicate that the “sandwich” protocol may benefit the long‐term survival of patients with newly diagnosed stage IE ‐ IIE , nasal type, extranodal natural killer/T‐cell lymphoma. However, additional studies with larger samples are required to confirm these results. This study is registered at www.Chictr.org (Chic TR ‐ TNC ‐09000394).